[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546745":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":23,"responsibleParty":41,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"RADIATION","Interventional Radiotherapy","The patients will undergo four IRT fractions in one week",[14],{"name":15,"affiliation":16,"role":17},"VALENTINA LANCELLOTTA","Fondazione Universiataria Policlinico A Gemelli IRCCS","PRINCIPAL_INVESTIGATOR",[19],{"name":15,"role":20,"phone":21,"phoneExt":7,"email":22},"CONTACT","3441177911","valentina.lancellotta@policlinicogemelli.it",[24],{"facility":25,"status":26,"city":27,"state":7,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Fondazione Policlinico Universitario A. Gemelli, IRCCS","RECRUITING","Rome","00168","Italy","IT",{"type":32,"coordinates":33},"Point",[34,35],12.51133,41.89193,{"lat":35,"lon":34},[38],{"name":39,"role":20,"phone":40,"phoneExt":7,"email":22},"Valentina Lancellotta","+0630159248",{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100546745","evaluation-of-ultraaccelerated-high-dose-rate-intrauterine-interventional-radiotherapy-100546745",false,"NCT06398938","Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy","EROS 3 Study Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy Brachytherapy in Terms of Overall Toxicity and Sexual Activity","EROS3","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG 0-2\n* Histological diagnosis of squamous carcinoma and\u002For adenocarcinoma of the uterine cervix\n* FIGO IB2 Stadium - IVA (staging 20018)\n* No contraindications to performing MRI of the pelvis\n* Informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* PS \\>2\n* Previous cancer in the last 10 years\n* Previous radiation treatment in the region of interest\n* Presence of pathologies that contraindicate radiotherapy treatment (genetic syndromes of hyper-radiosensitivity, ulcerative colitis, diverticulitis in the acute phase, severe diverticulosis, chronic pelvic inflammation)\n* Presence of internal diseases that contraindicate chemotherapy or radio-chemotherapy treatment (severe liver disease, heart disease, renal failure, etc.)\n* Presence of distant metastases in sites other than the pelvic lymph nodes\n* Any significant medical condition that in the opinion of the investigator may interfere with the patient's optimal participation in the study",true,"FEMALE","18 Years",{"count":55,"type":56},129,"ESTIMATED","OBSERVATIONAL","To evaluate the degree of acute and long-term intestinal, urinary and vaginal toxicity, and the impact on sexual activity of an accelerated fractionation of high dose rate interventional radiotherapy (IRT-HDR) in patients with locally advanced cervical cancer (IB2 - VA, N+\u002F-).",[60],"Locally Advanced Cervical Carcinoma",[62,63,64,65],"cervical carcinoma","interventional radiotherapy","acute and late toxicities","radiochemotherapy","2025-08-12",{"date":68,"type":69},"2025-08-15","ACTUAL",{"date":71,"type":69},"2024-05-06",{"date":73,"type":56},"2026-12-30",{"name":5,"class":6},1]